Stay updated on Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now indicates recruitment is closed. It also adds new guidance sections such as How to Read a Study Record, Common Questions, and How to Join a Study, and updates the Intervention/Treatment area along with a revision label v3.6.0.SummaryDifference0.3%

- Check21 days agoChange DetectedA new revision entry (Revision: v3.5.5) has been added along with new dates (2026-06-03, 2026-12-18, 2026-05-08, 2026-05). The previous revision (v3.5.4) was removed, signaling an update to IPD sharing materials and related study documents.SummaryDifference0.2%

- Check43 days agoChange DetectedThe page now shows a new Revision: v3.5.4 tag replacing the previous v3.5.3, indicating a minor update to the document version. This reflects metadata refresh rather than substantive changes to the study details.SummaryDifference0.0%

- Check58 days agoChange DetectedThe Taiwan site listing changes from Taoyuan, Taiwan, 333 to Taoyuan City, Taiwan, 333. This clarifies the city designation in the Locations list, aiding accurate site identification and search filters.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page’s revision identifier was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a minor site/version update rather than a change to the underlying study information.SummaryDifference0.0%

- Check72 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This appears to be a version bump with no changes to study details or user-facing information.SummaryDifference0.0%

Stay in the know with updates to Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.